Phase 3 N=45 Furosemide and Albumin for Diuresis of Edema: A Pilot Randomized Controlled Trial
Edema · Hypoproteinemia
Primary: Ventilator-free Days — 4; 13 days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=49 Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies
B-Lymphoid Malignancies · Acute Lymphocytic Leukemia · Chronic Lymphocytic Leukemia
Primary: Number of Events That Was Grade 3-4 Toxicities — 4; 1; 22; 1 events
N/A N=250 Evaluation of the Tof Cuff for Perioperative Neuromuscular Transmission
Neuromuscular Blockade
Primary: Depth of Neuromuscular Block During Moderate Neuromuscular Blockade (Outcome Measure/Row Title Train of Four Ratio) and During Deep Neuromuscular Blockade (Outcome…
Phase 3 N=1,078 A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.
Chronic Spontaneous Urticaria
Primary: Mean Change From Baseline in UAS7 at Week 12 (Multiple Imputation) of Adult Subjects — -19.218; -20.312; -19.632; -9.221 Scores on a scale — p=<.0001
Phase 3 N=892 Study in Primary Care Evaluating Inclisiran Delivery Implementation + Enhanced Support
Atherosclerotic Cardiovascular Disease · Atherosclerotic Cardiovascular Disease Risk Equivelents · Elevated Low Density Lipoprotein Cholesterol
Primary: Percentage Change in LDL-C From Baseline to Day 270 — -37.3; -37.6; -5.4 percent change from baseline in LDL-C — p=<0.001
Phase 4 N=70 Scaling and Root Planing (SRP) With and Without Minocycline HCl Microspheres, 1 mg
SRP · Minocycline HCl Microspheres · Biomarkers
Primary: Bacteria Load (log10) — -11.3; -10.9 log 10 copies/mL
N/A N=126 Weight Loss With Meal-Replacement Therapy in Teens
Obesity, Severe · Pediatric Obesity
Primary: Body Mass Index (From Baseline to 1-year) — -0.9; -6.6 Percent change in BMI
N/A N=40 In Person and mHealth Coping Skills Training for Symptom Management and Steps in Stem Cell Transplant Patients
Stem Cell Transplant
Primary: Feasibility as Measured by Number of Participants Accrued to the Study Within 16 Months — 28; 51; 4; 40 Participants
N/A N=30 Identifying Precursors to Severe Problem Behavior
Problem Behavior · Aggression
Primary: Severe Problem Behavior (SPB)
Phase 3 N=47 A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis
Moderate to Severe Plaque Psoriasis
Primary: Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16 — 0; 81.3 percentage of participants — p=<0.001
N/A N=279 PRESERFLO® MicroShunt Extension Study
Primary Open-angle Glaucoma
Primary: Incidence of Sight-threatening Adverse Events — 4; 0 Participants
Phase 3 N=551 A Trial to Assess the Efficacy and Safety of 400mg/Day Lacosamide in Subjects With Painful Diabetic Neuropathy
Painful Diabetic Neuropathy
Primary: Change in Average Daily Pain Score From Baseline Week to the Last 4 Weeks of the Maintenance Phase — -1.9; -2.2; -2.4 units on a scale — p==0.0410
Phase 3 N=485 Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) SPIROMAX® as Compared to SYMBICORT® TURBOHALER® as Treatment for Adult Participants With Asthma
Asthma
Primary: Stage 1: Percentage of Participants Achieving Device Mastery — 94.4; 86.9 percentage of participants — p=<0.001
Phase 3 N=17 A Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Participants With Primary Immunodeficiency Diseases (PID)
Primary Immunodeficiency Diseases (PID)
Primary: Epoch 2: Total Serum Trough Levels of Immune Globulin G (IgG) Antibodies During Period 2 — 8.56 grams per liter (g/L)
N/A N=30 Mobile Technology for Blood Pressure Management
Hypertension
Primary: Change in Blood Pressure — -14.5; -6.3 mmHg